Publicación:
Characterizing trachoma elimination using serology

dc.contributor.authorKamau, Everlyn
dc.contributor.authorAnte-Testard, Pearl Anne
dc.contributor.authorGwyn, Sarah
dc.contributor.authorBlumberg, Seth
dc.contributor.authorAbdalla, Zeinab
dc.contributor.authorAiemjoy, Kristen
dc.contributor.authorAmza, Abdou
dc.contributor.authorAragie, Solomon
dc.contributor.authorArzika, Ahmed M.
dc.contributor.authorAwoussi, Marcel S.
dc.contributor.authorBailey, Robin L.
dc.contributor.authorButcher, Robert
dc.contributor.authorCallahan, E. Kelly
dc.contributor.authorChaima, David
dc.contributor.authorDawed, Adisu Abebe
dc.contributor.authorDíaz, Martha Idalí Saboyá
dc.contributor.authorDomingo, Abou-Bakr Sidik
dc.contributor.authorDrakeley, Chris
dc.contributor.authorElshafie, Belgesa E.
dc.contributor.authorEmerson, Paul M.
dc.contributor.authorFornace, Kimberly
dc.contributor.authorGass, Katherine
dc.contributor.authorGoodhew, E. Brook
dc.contributor.authorHammou, Jaouad
dc.contributor.authorHarding-Esch, Emma M.
dc.contributor.authorHooper, P.J.
dc.contributor.authorKadri, Boubacar
dc.contributor.authorKalua, Khumbo
dc.contributor.authorKanyi, Sarjo
dc.contributor.authorKasubi, Mabula
dc.contributor.authorKello, Amir B.
dc.contributor.authorKo, Robert
dc.contributor.authorLammie, Patrick J.
dc.contributor.authorLescano, Andres G.
dc.contributor.authorMaliki, Ramatou
dc.contributor.authorMasika, Michael Peter
dc.contributor.authorMigchelsen, Stephanie J.
dc.contributor.authorNassirou, Beido
dc.contributor.authorNesemann, John M.
dc.contributor.authorParameswaran, Nishanth
dc.contributor.authorPomat, Willie
dc.contributor.authorRenneker, Kristen K.
dc.contributor.authorRoberts, Chrissy
dc.contributor.authorRymil, Prudence
dc.contributor.authorSata, Eshetu
dc.contributor.authorSenyonjo, Laura
dc.contributor.authorSeife, Fikre
dc.contributor.authorSillah, Ansumana
dc.contributor.authorSokana, Oliver
dc.contributor.authorSrivathsan, Ariktha
dc.contributor.authorTadesse, Zerihun
dc.contributor.authorTaleo, Fasihah
dc.contributor.authorTaylor, Emma Michelle
dc.contributor.authorTekeraoi, Rabebe
dc.contributor.authorTogbey, Kwamy
dc.contributor.authorWest, Sheila K.
dc.contributor.authorWickens, Karana
dc.contributor.authorWilliam, Timothy
dc.contributor.authorWittberg, Dionna M.
dc.contributor.authorYeboah-Manu, Dorothy
dc.contributor.authorYoubi, Mohammed
dc.contributor.authorZeru, Taye
dc.contributor.authorKeenan, Jeremy D.
dc.contributor.authorLietman, Thomas M.
dc.contributor.authorSolomon, Anthony W.
dc.contributor.authorNash, Scott D.
dc.contributor.authorMartin, Diana L.
dc.contributor.authorArnold, Benjamin F.
dc.date.accessioned2026-05-01T06:26:37Z
dc.date.issued2025
dc.description.abstractTrachoma is targeted for global elimination as a public health problem by 2030. Measurement of IgG antibodies in children is being considered for surveillance and programmatic decision-making. There are currently no programmatic guidelines based on serology, which represents a generalizable problem in seroepidemiology and disease elimination. Here, we collate Chlamydia trachomatis Pgp3 and CT694 IgG measurements from 48 serosurveys across Africa, Latin America, and the Pacific Islands (41,168 children ages 1–5 years) and propose a novel approach to estimate the probability that population C. trachomatis transmission is below or above levels requiring ongoing programmatic action. We determine that trachoma programs could halt control measures with >90% certainty when seroconversion rates (SCRs) are ≤2.2 per 100 person-years. Conversely, SCRs ≥4.5 per 100 person-years correspond with >90% certainty that further control interventions are needed. More extreme SCR thresholds correspond with higher levels of confidence of elimination (lower SCR) or ongoing action needed (higher SCR). This study demonstrates a robust approach for using trachoma serosurveys to guide elimination program decisions. © The Author(s) 2025.en_US
dc.description.sponsorshipFunding text 1: This work was supported by the National Institutes of Health (NIAID R01AI158884 to B.F.A., NIGMS R35GM147702 to S.B.). A.B.K., A.W.S, and F.T. are staff members of the World Health Organization. Disclaimer: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the funding agencies. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.; Funding text 2: K.K.R., P.J.H., and P.M.E. are employees of, and E.M.H.E. receives salary support from, the International Trachoma Initiative, which receives an operating budget and research funds from Pfizer Inc., the manufacturers of Zithromax\u00AE (azithromycin). The other authors declare no competing interests.es_PE
dc.identifier.doihttps://doi.org/10.1038/s41467-025-60581-z
dc.identifier.scopus2-s2.0-105009728134
dc.identifier.urihttps://hdl.handle.net/20.500.12866/19476
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofurn:issn:2041-1723
dc.relation.ispartofseriesNature Communications
dc.relation.issn2041-1723
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.titleCharacterizing trachoma elimination using serologyen_US
dc.typehttps://purl.org/coar/resource_type/c_2df8fbb1
dc.type.localArtículo de revista
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Archivos